Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 689 of 5804
-
New drug combo may unlock transplants for 'Impossible-to-Match' kidney patients
Disease control CompletedSome kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an accepta…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New chemo combo shows promise for deadly bile duct cancer
Disease control CompletedBiliary drainage and stent placement remains to be the main palliative treatment choice for advanced perihiliar cholangiocarcinoma (pCCA), and the life expectancy is only 4-6 months. Previous single center prospective phase 2 trial showed that hepatic arterial infusion chemothera…
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Eye injection may save sight in kids with rare batten disease
Disease control OngoingThis is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.
Phase: PHASE1, PHASE2 • Sponsor: David L Rogers, MD • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Massive study aims to map hepatitis c elimination in pakistan
Knowledge-focused CompletedWe will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, base…
Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Phone app predicts relapse to stop opioid abuse during treatment
Disease control Recruiting nowTreatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute b…
Phase: PHASE3 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedPart I (Clinical trial setting): A single-arm phase II study to investigate the efficacy of neoadjuvant atezolizumab (T) + bevacizumab (A) in patients with potentially resectable BCLC stage B/C or high risk resectable hepatocellular carcinoma (HCC) (n = 40) Part II (Biomarker st…
Phase: PHASE2 • Sponsor: Tae Won Kim • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New MRI scan could replace endoscopy for liver patients
Diagnosis CompletedThe goal of this research is to validate novel non-invasive Magnetic resonance imaging (MRI) biomarkers to detect Gastroesophageal varices (GEV) in patients with cirrhosis, including fractional flow change in the portal vein and elevated azygos flow. End-stage liver disease (cir…
Sponsor: University of Wisconsin, Madison • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
New vaccine combo aims to supercharge immune attack on aggressive breast cancer
Disease control Recruiting nowThe purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare kidney cancer: drug combo shows promise in late-stage trial
Disease control OngoingA clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Precision radiation aims to stall prostate cancer spread
Disease control Recruiting nowThe study is an open label, multi-centre, randomized phase III study. The patients will be randomised in a 1:1 ratio to treatment consisting of * Arm A: MD-SBRT in addition to standard treatment * Arm B: Standard treatment Study population: Patients with hormone sensitive prost…
Phase: NA • Sponsor: Karin Soderkvist • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill could help adults with low platelet disorder
Disease control CompletedThe purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug may cut transfusions for MDS patients
Disease control OngoingA phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for tough lung cancers: drug combo trial launches
Disease control OngoingThe goal of this clinical trial is to compare the safety and efficacy (how well the drug works) of acasunlimab (also known as GEN1046) when it is used alone (monotherapy) versus when it is combined with a cancer drug (pembrolizumab) for participants with relapsed/refractory (dise…
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Heart drug acoramidis tested for Long-Term safety in rare amyloidosis
Disease control OngoingOpen-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
ER shock showdown: less fluid, early pressors vs. standard care
Disease control OngoingThis multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and e…
Phase: PHASE3 • Sponsor: Australian and New Zealand Intensive Care Research Centre • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New mRNA vaccine aimed at preventing common but risky virus
⭐️ VACCINE ⭐️ TerminatedThe main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants. The purpose of the Phase 3 extension substudy is to extend the observati…
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:04 UTC
-
Lupus drug trial hopes to tame flares with targeted antibody
Disease control OngoingThis parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced breast cancer: experimental drug targets tumors after other treatments fail
Disease control OngoingA Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Phase: PHASE2 • Sponsor: Ambrx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Step transplant aims to cut deaths in blood cancer patients
Disease control Recruiting nowThis phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malig…
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill targets tough lung cancers in first human trial
Disease control Recruiting nowResearchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body. Epidermal growth factor receptor (EGFR) and human epidermal growth factor rece…
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC